Clifutinib - CISMeF

Preferred Label : Clifutinib;

NCIt definition : An orally bioavailable, selective, small molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, clifutinib targets, binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.;

NCI Metathesaurus CUI : CL1663048;

Détails

Origin ID

C180527;

UMLS CUI

C5556443;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_salt_form
- Clifutinib Besylate [NCIt concept]
has_target
- Receptor-Type Tyrosine-Protein Kinase FLT3 [NCIt concept]
is_free_acid_or_base_form_of
- Clifutinib Besylate [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients